Please login to the form below
Moderna
This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
Moderna inks R&D agreements with Vertex and Chiesi
In its agreement with Vertex, Moderna will receive $75m to collaborate on the research and development into gene therapies for CF. ... the use of gene editing in lung cells,” said Stéphane Bancel, chief executive officer of Moderna.
Latest news
-
Top biopharma CEOs sign COVID-19 vaccine safety pledge
The pledge was co-signed by the CEOs of nine pharma and biotech companies, including the leaders of AstraZeneca, Johnson &Johnson, Merck, Moderna and Novavax as well as Pfizer and BioNTech,
-
American Medical Association calls for COVID-19 vaccine development transparency
Among the companies selected to receive funding as part of the initiative includes Johnson &Johnson, AstraZeneca/Oxford University, Pfizer/BioNTech, GlaxoSmithKline/Sanofi, Moderna and Novavax.
-
Moderna’s COVID-19 vaccine shows promise in older adults
group. Moderna’s shot also produced superior antibody levels in study participants compared to the levels seen in recovered COVID-19 patients. ... As part of Operation Warp Speed, Moderna will receive up to $1.5bn for advancing the development and
-
Translate Bio, Sanofi's COVID-19 vaccine proves promising in animal studies
Another promising mRNA vaccine candidate, being development by frontrunner Moderna, produced antibodies against COVID-19 in all participants tested in a phase 1 trial.
-
EU concludes discussions with Moderna for COVID-19 vaccine
Moderna is the fifth company with which the EC has concluded such talks, which includes Sanofi/GlaxoSmithKline, Johnson &Johnson, CureVac and AstraZeneca. ... The US, under it’s Operation Warp Speed initiative, will also have the option to purchase up
More from news
Approximately 14 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
COVID-19: the race to find a vaccine
Moderna was the first group to test a vaccine in humans, using its mRNA platform to enter the clinic in record time. ... Moderna thinks its vaccine could be available to healthcare professionals as early as the autumn, but the accepted timeline for
-
Developing a COVID-19 vaccine
At the front of the race is Cambridge, Massachusetts-based biotech company Moderna, which dosed the first patient in the US in March with its COVID-19 vaccine candidate. ... To win approval for public use, a larger phase 2 trial is need, which Moderna
-
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to
-
Deal Watch June 2016
Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).
-
Deal Watch October 2015
Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
Horning has also recently joined the board of directors at Moderna, a clinical-stage biotechnology company based in Cambridge, Massachusetts.
-
Tony de Fougerolles joins Evox Therapeutics as CEO
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
-
Medicxi appoints former GSK chair Moncef Slaoui
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
-
MIT chief financial officer joins Moderna Therapeutics
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
-
PureTech Health appoints chief scientific officer
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Keytruda doubles five-year survival rate in NSCLC
- FDA approves Roche’s Actemra COVID-19 trial
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
- World Heart Day 2020: It's time to make our clinical trials more inclusive
- September 29th is World Heart Day, a day dedicated to raising awareness about cardiovascular diseases and how everyone can take steps to prevent them. It’s common knowledge that smoking and...
Quick links
Infographics
